Headless WordPress - PROD

New treatments shift focus from complication surveillance to modulating FGFR3 signaling pathways

https://sharecareprofessional.top/hcp/genetic-disorders-birth-defects/beyond-symptomatic-management-molecular-targeting-achondroplasia

Beyond symptomatic management: Molecular targeting in achondroplasia

Expanding treatment eligibility from infancy highlights the importance of timely diagnosis and therapeutic access

https://sharecareprofessional.top/hcp/genetic-disorders-birth-defects/redefining-early-intervention-critical-window-growth-modulation

Redefining early intervention: The critical window for growth modulation

Diverse pharmacologic targets and formulations expand options for personalized achondroplasia management

https://sharecareprofessional.top/hcp/genetic-disorders-birth-defects/achondroplasia-treatment-strategies-combination-approaches

Evolving treatment strategies: From single mechanism to combination approaches

Featured Content

Dx Dialogues: Achondroplasia

Pediatric endocrinologist and geneticist Dr. Nadia Merchant, MD, Associate Professor of Pediatrics, explores breakthroughs in achondroplasia care, from earlier diagnosis to the latest therapeutic developments shaping treatment today.
[Video Medical Glossary - CNP: C-type natriuretic peptide;

NPR-B: natriuretic peptide receptor-B;

cGMP: cyclic guanosine monophosphate;

MAPK: mitogen-activated protein kinase;

FGFR3: fibroblast growth factor receptor 3]